PMID- 32269504
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1559-3258 (Print)
IS  - 1559-3258 (Electronic)
IS  - 1559-3258 (Linking)
VI  - 18
IP  - 1
DP  - 2020 Jan-Mar
TI  - Potential Role of the Micro-Immunotherapy Medicine 2LALERG in the Treatment of 
      Pollen-Induced Allergic Inflammation.
PG  - 1559325820914092
LID - 10.1177/1559325820914092 [doi]
LID - 1559325820914092
AB  - In this study, we evaluated the efficacy of a micro-immunotherapy medicine (MIM), 
      2LALERG, in a preclinical model of allergic respiratory disease sensitized with 
      birch pollen extract (BPE). BALB/c mice were immunized with BPE, or saline 
      solution, and were then challenged. Micro-immunotherapy medicine pillules were 
      diluted in water, and 3 doses (0.75; 1.5; 3 mg/mouse) were tested and compared to 
      vehicle control (3 mg/mouse). Treatments and vehicle were orally administered by 
      gavage for 10 days. Micro-immunotherapy medicine (0.75 mg/mouse) reduced the 
      number of total cells as well as the levels of interleukin (IL)-13 in 
      bronchoalveolar lavage fluid (BALF) compared to vehicle control. Eosinophils in 
      BALF tended to be lower compared to vehicle group, and the difference is close to 
      significance. Histological analysis in the lungs confirms a moderate effect of 
      MIM (0.75 mg/mice) on inflammatory infiltration and mucus production. Serum 
      levels of IL-5 in MIM (0.75 mg/mouse)-treated mice were lower compared to 
      vehicle; IL-4 levels tended to be lower too. Total immunoglobulin E (IgE) 
      decreased in serum of MIM (1.5 and 0.75 mg/mouse) groups compared to vehicle 
      control. Micro-immunotherapy medicine exerted the highest effect at the lowest 
      dose tested. Micro-immunotherapy medicine resolved the local and systemic 
      inflammation, even if partially, in a model of pollen-induced, IgE-mediated 
      inflammation.
CI  - (c) The Author(s) 2020.
FAU - Floris, Ilaria
AU  - Floris I
AUID- ORCID: 0000-0003-4089-3133
AD  - Preclinical & Clinical Development and Regulatory Affairs, Labo'Life France, 
      Nantes, France.
FAU - Chenuet, Pauline
AU  - Chenuet P
AD  - ArtImmune, Orleans, France.
FAU - Togbe, Dieudonnee
AU  - Togbe D
AD  - ArtImmune, Orleans, France.
FAU - Volteau, Christelle
AU  - Volteau C
AD  - Preclinical & Clinical Development and Regulatory Affairs, Labo'Life France, 
      Nantes, France.
FAU - Lejeune, Beatrice
AU  - Lejeune B
AUID- ORCID: 0000-0001-9067-6116
AD  - Preclinical & Clinical Development and Regulatory Affairs, Labo'Life France, 
      Nantes, France.
LA  - eng
PT  - Journal Article
DEP - 20200324
PL  - United States
TA  - Dose Response
JT  - Dose-response : a publication of International Hormesis Society
JID - 101308899
PMC - PMC7093691
OTO - NOTNLM
OT  - IgE-mediated inflammation
OT  - low doses
OT  - micro-immunotherapy
OT  - pollen-induced allergy
OT  - ultra-low doses
COIS- Declaration of Conflicting Interests: The author(s) declared the following 
      potential conflicts of interest with respect to the research, authorship, and/or 
      publication of this article: BL, IF, and CV work for Labo'Life France, the 
      company service provider of Labo'Life, specialized in pre-clinical, clinical 
      development, and regulatory affairs. This professional relationship does not 
      imply any misconduct on the part of the authors. DT and PC work for ArtImmune, a 
      biotechnological company specialized in preclinical research.
EDAT- 2020/04/10 06:00
MHDA- 2020/04/10 06:01
PMCR- 2020/03/24
CRDT- 2020/04/10 06:00
PHST- 2019/10/22 00:00 [received]
PHST- 2020/02/19 00:00 [revised]
PHST- 2020/02/25 00:00 [accepted]
PHST- 2020/04/10 06:00 [entrez]
PHST- 2020/04/10 06:00 [pubmed]
PHST- 2020/04/10 06:01 [medline]
PHST- 2020/03/24 00:00 [pmc-release]
AID - 10.1177_1559325820914092 [pii]
AID - 10.1177/1559325820914092 [doi]
PST - epublish
SO  - Dose Response. 2020 Mar 24;18(1):1559325820914092. doi: 10.1177/1559325820914092. 
      eCollection 2020 Jan-Mar.